Skip to main content

Table 2 Ratio (R/S) of replacement mutations to silent mutations in regions of Vλ in a patient with SLE and in normal human subjects

From: Perturbations in the impact of mutational activity on Vλ genes in systemic lupus erythematosus

  Patient with SLE Normal subjects*
Region of Vλ Nonproductive rearrangements Productive rearrangements Nonproductive rearrangements Productive rearrangements
FR1 1.0b (4/4) 7.3b (29/4) 0.0 (0) 1.8 (9/5)
CDR1 7.8 (47/6) 6.3a (113/18) 3.0 (12/4) 3.9a (55/14)
FR2 3.1 (49/16) 2.5 (95/38) 0.0b (11/0) 1.8b (51/29)
CDR2 8.2 (41/5) 10.9 (76/7) 10.0 (10/1) 4.8 (48/10)
FR3 2.9 (112/39) 3.1 (185/59) 4.0 (12/3) 2.4 (66/28)
CDR3 8.7 (52/6) 8.0a (96/12) 3.0 (15/5) 3.7a (81/22)
FRs 2.8 (165/59) 3.1a (309/101) 7.7b (23/3) 2.0a,b (126/62)
CDRs 8.2 (140/17) 7.7a (285/37) 3.7 (37/10) 4.0a (184/46)
Total 4.0 (305/76) 4.3a (594/138) 4.6 (60/13) 2.9a (310/108)
  1. *The data for normal subjects have been published elsewhere [23]. aSignificant difference between ratio in SLE patient and normal subjects; P < 0.05 (Χ2 test). bSignificant difference between ratio in nonproductive and productive rearrangements; P < 0.05 (Χ2 test). CDR = complementarity-determining region; FR = framework region.